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Objective. Possible differences in splicing variants of TGIF1 in oral squamous cell carcinoma (OSCC) have not yet been
reported. This study analyzed the expression levels of different splicing variants of the TGIF1 gene in OSCC compared with
nontumoral epithelium (NT) and the relationship with clinical-pathologic features of tumors.
Study Design. Forty-eight frozen samples of OSCC and 17 of NT were analyzed using quantitative reverse transcription
polymerase chain reaction.
Results. TGIF1v2 and v8 are overexpressed in OSCC, whereas TGIF1v5 is underexpressed when compared with NT. Low
TGIF1v8 expression was correlated with lower cellular differentiation, positive blood vascular invasion, advanced pathologic
stage, and positive vascular lymphatic invasion of OSCC. TGIF1v8 is also related to overall survival over time, with lower
values associated with an increased risk of cancer-related death.
Conclusions. These data suggest that alternative splicing of TGIF1 is deregulated in OSCC, with overexpression of some
splicing variants, especially TGIF1v8, which is associated with advanced stages of OSCC. (Oral Surg Oral Med Oral Pathol
Oral Radiol 2013;116:614-625)Squamous cell carcinoma is one of the most common
cancers of the oral cavity, accounting for at least 90%
of all oral malignancies.1 It is a universal, aggressive
disease that usually affects smokers and alcohol drinkers.
Despite improved diagnostic and therapeutic methods
over the past 20 years, oral squamous cell carcinoma
(OSCC) still has high morbidity and mortality rates.2-3
Unfortunately, there is no genetic proﬁle for OSCC,
and the mechanisms for carcinogenesis are not yet fully
understood. The last decade has seen signiﬁcant progressThis work was supported by FAPESP grants 01/13644-6, CAPES and
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614in understanding the molecular alterations that lead to
oncogenic transformation, and there has been an exten-
sive search for biomarkers that could predict the clinical
behavior of this cancer.4-7 Several research groups are
dedicated to studying genes related to embryo develop-
ment, which are also important in carcinogenesis. These
genes can provide insights into processes that differ
between normal and neoplastic cells, such as cellular
communication, migration, growth, differentiation, and
apoptosis, because many of the molecular pathways that
underlie carcinogenesis are aberrations of normal
developmental processes.8,9 A family of genes closely
related to embryonic development is the homeobox
family. Several studies have found that homeobox genes
have an altered expression in many solid cancers,
including skin, colon, prostate, breast, ovary, kidney,
lung, thyroid, and esophageal cancer, and also in non-
solid cancers such as leukemia.10 Recent publications
have described the participation of homeobox genes in
OSCC.11-15
A previous study found that TGIF1 transcripts were
expressed differently in OSCC according to histologic
grading.14 TGIF1 belongs to the homeobox family ofStatement of Clinical Relevance
This study adds information pertinent to cancer
genetics and biomarkers of oral squamous cell
carcinoma, because it highlights TGIF1 splicing
variants possible role in oral carcinogenesis.
OOOO ORIGINAL ARTICLE
Volume 116, Number 5 Libório et al. 615transcription factors and is alternatively spliced into 8
different splicing variants, encoding 4 distinct protein
isoforms (http://ncbi.nlm.nih.gov, Gene ID 7050).
However, Hamid et al.10 suggested that the TGIF1 gene
has 12 splice isoforms. This gene is a member of the
3-amino-acid loop extension superclass of atypical
homeodomains and seems to act in multiple transcrip-
tional regulatory pathways, either as a DNA binding
repressor or as a corepressor in association with other
DNA binding proteins.16 TGIF1 has been implicated in
the etiology of holoprosencephaly and is expressed in
esophageal, gastric, and liver cancer and leukemia.17-20
Alternative splicing is a process by which exons
from the same gene can be combined in different
ways, resulting in different messenger ribonucleic acid
(mRNA) variants, increasing transcriptome diversity
and proteome complexity.21 Alterations of the alterna-
tive splicing process have been associated with many
human diseases, especially cancer.22-26 The identiﬁca-
tion of splicing variants associated with cancer may
improve the understanding of cancer biology, contribute
to the development of diagnostic protocols and prog-
nosis estimation, and suggest therapeutic targets.
This study reports the expression of TGIF1 splicing
variants in OSCC compared with nontumoral epithe-
lium (NT) and describes TGIF1 protein expression in
the same group of patients.
MATERIALS AND METHODS
Samples collection and preparation
This study was approved by the Human Research
Ethics Committee of the A.C. Camargo Hospital, São
Paulo, Brazil. Fresh tissue samples were obtained from
48 patients with OSCC after surgical resection at the
A.C. Camargo Hospital’s Head and Neck Surgery and
Otorhinolaryngology Department. Seventeen NT
samples were also obtained from morphologically
normal surgical margins of patients with OSCC,
selected by gross examination, and conﬁrmed by
microscopic analysis. Samples were snap-frozen in
liquid nitrogen immediately after surgical excision.
After histologic conﬁrmation, fresh-frozen tissue from
each sample was microdissected, after cryostat
sectioning and toluidine blue staining, to ensure the
removal of at least 70% to 80% of epithelial tumor
cells. An expert pathologist reported the corresponding
surgical margin as “tumor-free.” For all cases, the
following information was recorded: age, gender, site
of primary tumor, histologic grading, extent of inﬁl-
tration, lymphatic and blood invasion, treatment, and
follow-up. The criteria for differentiating lymphatics
from blood capillaries were based on microscopic
examination using hematoxylin-eosin staining. The
histologic grading was in line with World Health
Organization guidelines27: well-differentiated OSCC(sheets and nests of neoplastic cells highly keratinized);
moderately differentiated OSCC (less keratinized, and
inﬁltrating solid cords and nests); and poorly differen-
tiated OSCC (minimal keratinization, and small groups
of cells or single cells). The clinical-pathologic data and
follow-up (time from diagnosis until death or latest
information) are summarized in Table I.RNA isolation and complementary DNA
synthesis
Total RNA was extracted from frozen samples using
the TRIzol method (Invitrogen, Gaithersburg, MD,
USA), according to the manufacturer’s instructions.
RNA was quantiﬁed by absorbance reading at 260 nm,
and the integrity was evaluated on agarose gel stained
with ethidium bromide. Complementary DNA (cDNA)
synthesis was carried out using 1 mg of total RNA in the
presence of Oligo-dT (a short sequence of deoxy-
thymine nucleotides) (0.5 mg/mL) by reverse tran-
scriptase enzymes SuperScript II (Invitrogen) or
ImProm-II (Promega, Madison, WI, USA), according
to the manufacturer’s instructions, in a 20-mL reaction
mixture.Quantitative reverse transcription polymerase
chain reaction
For the ampliﬁcation reactions, the study designed
speciﬁc primers for the splicing variants 1, 2, 5, 7, and 8
(TGIF1v1, v2, v5, v7, and v8, respectively) and
a generic primer (TGIF1) amplifying a region common
to all splicing variants (Table II); the amplicon was then
conﬁrmed through sequencing. For normalization, the
GAPDH housekeeping gene (which encodes for glyc-
eraldehyde 3-phosphate dehydrogenase) was used.
Primers were designed to amplify interexon regions,
using Gene Tool 2.0 software (Bio Tools Inc.: http://
genetool.software.informer.com/) (Figure 1).
Quantitative reverse transcription polymerase chain
reaction (RT-qPCR) was carried out using the ABI
Prism 7000 Sequence Detection System (Applied Bio-
systems, Carlsbad, CA, USA). All reactions were
duplicated and contained 10 mL of SYBR Green PCR
Master Mix (Applied Biosystems), 10 to 40 ng of
cDNA, and 200 to 800 mM of each primer at a ﬁnal
volume of 20 mL. The RT-qPCR reactions were opti-
mized for each pair of primers according to the manu-
facturer’s recommendations. The standard thermal
cycle (denaturation at 95C for 10 minutes) was used,
followed by 40 cycles of denaturation at 95C for 15
seconds, and annealing at 60C to 64C for 60 seconds.
The ampliﬁcation efﬁciency (E) was calculated for each
gene using data collected from a standard curve with
the following formula: E ¼ 10(1/slope). The slope was
obtained from the data collected during the exponential
Table I. Clinical-pathologic data and follow-up time of
patients with OSCC
Clinical-pathologic features No. of cases Percentage
Gender
Male 40 83.3%
Female 8 16.7%
Age
40-60 years 28 58.3%
>60 years 20 41.7%
Alcohol (*)
Yes 37 84.1%
No 7 15.9%
Smoke (*)
Yes 43 91.5%
No 4 8.5%
Tumor location
Tongue 20 41.7%
Floor of mouth 13 27.1%
Gingiva 4 8.3%
Retromolar region 5 10.4%
Palate 4 8.3%
Buccal mucosa 2 4.2%
pN (nodal metastasis)
classiﬁcation (*)
Nþ 25 53.2%
N 22 46.8%
pT (tumor size) classiﬁcation (*)
T1/T2 (4 cm) 33 70.2%
T3/T4 (>4 cm) 14 29.8%
Pathologic TNM stage (*)
I/II (early) 17 36.2%
III/IV (advanced) 30 63.8%
Histologic grading (*)
Well differentiated 26 57.8%
Moderately differentiated 19 42.2%
Poorly differentiated 2y
Perineural invasion (PI) (*)
PIþ 22 47.8%
PI 24 52.2%
Vascular invasion (VI) (*)
VIþ 4 9.1%
VI 40 90.9%
Lymphatic invasion (LI) (*)
LIþ 10 22.2%
LI 35 77.8%
Death/cause
Yes/cancer 18 37.5%
Yes/comorbidity 5 10.4%
No 25 52.1%
Status/follow-up
Death from cancer (*) 12
months
10 21.3%
>12 months 7 14.9%
Death from comorbidity, 79.5
months
5 10.6%
Alive 41 months 9 19.2%
>41 months 16 34%
*Cases with missing data.
yDisregarded.
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reference cDNA (100, 20, 4, 0.8, and 0.16 ng) for each
gene.Total RNA from a human breast cell line
(HB4aC5.2) was used as a calibrated sample for all
reactions, and the relative fold was calculated as
described by Pfafﬂ28 using the mean value of the
replicates. Speciﬁcations of primer and cDNA
concentration, melting temperature, and efﬁciency of
primer for each set of primers are available on request.
The number of cases varied for each set of primers:
TGIF1 (OSCC 48/48; NT 16/17), TGIF1v1 (OSCC 45/
48; NT 17/17), TGIF1v2 (OSCC 42/48; NT 16/17),
TGIF1v5 (OSCC 40/48; NT 9/17), TGIF1v7 (OSCC
39/48; NT 11/17), TGIF1v8 (OSCC 23/48; NT 8/17),
and GAPDH (OSCC 48/48; NT 17/17).
Immunohistochemistry
Tissue microarray construction. The specimens used
for tissue microarray (TMA) were obtained from the
same patients whose tissue were subject to mRNA
analysis. Twenty-four formalin-ﬁxed parafﬁn-embedded
tissues from 48 OSCC surgical specimens and 9 from 17
NT specimens were used. In brief, a TMA parafﬁn
receptor block (Beecher Instruments, Silver Spring, MD,
USA) was constructed from the samples collected from
the original donor block using a 0.6-mm-diameter needle
(TMArrayer Punch; Beecher Instruments) after previous
selection and circular marking of the representative area
of the tumor on the original hematoxylin-eosinestained
slide. The cases were placed on the receptor block in
ascending numerical order. Serial 3-mm thick histologic
cuts were made and ﬁxed on glass slides with adhesive
ﬁlm (Microsystems Inc, Downers Grove, IL, USA). The
TMA was veriﬁed on a hematoxylin-eosinestained
section after construction.
Immunohistochemical assay and the quantitation
method. Immunohistochemistry was carried out following
the polymer-based immunohistochemistry method using
goat polyclonal antibody TGIF1 (H-172; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) raised against a
fragment corresponding to amino acids 100-272 mapping
to the C-terminus of TGIF1; this antibody recognizes all
TGIF1 isoforms. Initially, sections were deparafﬁnized in
xylene and rehydrated through a graded ethanol series. To
quench endogenous peroxidase, sections were incubated
with 3% hydrogen peroxide in methanol for 30 minutes at
room temperature, and then antigen retrieval was carried
out using a water bath (95C) treatment for 30 minutes
in 10 mM of ethylenediaminetetraacetic acid solution
(pH 8.0). After washing twice with Tris-HCl buffer
(pH 7.4), sections were preincubated with a swine serum
(X0912; DAKO, Glostrup, Denmark) for 30 minutes at
room temperature to prevent nonspeciﬁc protein
binding. Sections were incubated overnight at 4C in
a moist chamber with primary antibody diluted at
1:300. Afterward, the secondary reaction was carried
out using EnVision þ Dual Link System Peroxidase
Fig. 1. N- and C-terminal regions of the TGIF1 splicing variant (Gene ID:7050). The C-terminal region is similar for all splicing
variants. The discrimination between splicing variants depends on its N-terminal region. Observe the genomic region for each pair
of primers on interexon positions (arrows).
Table II. Primers used for generic and speciﬁc splicing variants of TGIF1, according to access number, orientation,
and product size
Gene Accession No.
Primers (5030)
Amplicon (bp)Sense Antisense
TGIF1 NM_170695 cttcgggattggctgtatga ggcgggaaattgtgaactg 190
TGIF1v1 NM_170695 gccgactcctggaaacaatga agccagcggatgaagaaaggt 105
TGIF1v2 NM_173207 agtgcctcgccagctttaac ccagcggatgaagaaaggtc 169
TGIF1v5 NM_173209 cccgagggacgagtgacagc agccagcggatgaagaaaggt 135
TGIF1v7 NM_173211 accctccccaccgccacatt agccagcggatgaagaaaggt 108
TGIF1v8 NM_174886 cctccacttccacattccag gagccagcggatgaagaaag 120
GAPDH NM_002046.3 gaaggtgaaggtcgga gggtcattgatggcaac 102
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drochloride was used as a chromogen (K3468; DAKO).
The slides were rinsed and counterstained withMayer’s
hematoxylin. Internal positive controls consisted of
normal plasma cells of the surrounding stroma.
Immunohistochemical staining was evaluated quanti-
tatively using the ACIS III (Automated Cellular
Imaging System; Dako, Carpinteria, CA, USA).
The ACIS system consisted of an automated robotic
bright-ﬁeld microscope module, a computer, and a
Windows NTebased software interface. The roboticmicroscope module scanned the immunohistochemically
stained slides, and a computer monitor displayed the
digitized tissue images; it was possible to detect, count,
and classify cells based on color, shape, and size. The
ACIS recognized 256 levels of immunohistochemical
staining intensity and converted these to fractional
scores for the selected individual areas. A mean score
for all selected areas was also calculated. To analyze
the TGIF1 immunoexpression, a nuclear analysis appli-
cation program was used, to obtain the nuclear com-
ponent percentage. In addition, a cytoplasmic analysis
ORAL AND MAXILLOFACIAL PATHOLOGY OOOO
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the cytoplasmic signal. The ACIS III analysis took place
at the Department of Pathology and Anatomy, A.C.
Camargo Hospital.Statistical analysis
The Mann-Whitney test, which is a nonparametric test
used in situations with inexistence of normal distribu-
tion of data, was used to compare the OSCC and NT
samples for mRNA TGIF1 splicing variants and for
protein expression. The Mann-Whitney test was also
used to assess the association between selected splicing
variants and protein regarding clinical-pathologic
features such as gender, nodal metastasis (pN), tumor
size (pT), pathologic tumor-nodes-metastasis (TNM)
stage (early, I/II; advanced, III/IV), histologic grading
(well-differentiated, moderately differentiated, and
poorly differentiated), perineural invasion, vascular
invasion, and lymphatic invasion. The Kruskal-Wallis
test was used to assess the anatomic site regarding
selected splicing variants and protein.
Correlations were assessed using the Spearman test
for mRNA and protein expression, age, and follow-up
in the OSCC samples. The parameters used were the
Spearman correlation coefﬁcient (r), with values
ranging from 1 to 1, and the P value hypothesis test:
H0: r ¼ 0 and H1: r s 0. The closer j r j is to 1, the
better the correlation between the 2 measurements
assessed. A signiﬁcant correlation (s 0) is present
when H0 is rejected. To evaluate the correlation grade,
the following criteria were considered: j r j < 0.4, weak
correlation; 0.4  j r j < 0.7, moderate correlation; 0.7
 j r j < 0.9, strong correlation; and 0.9  j r j  1,
very strong correlation. A negative value indicates
a decrease in a measurement as the other increases, and
a positive value indicates an increase in a measurement
as the other also increases.
The overall survival of patients, deﬁned as time from
surgery to the day of death or last follow-up, was
calculated using the Kaplan-Meier product-limit esti-
mation with the log-rank test, the Breslow method, and
the Cox regression model (multivariate analysis). A
commercially available software package (SPSS,
version 16.0; SPSS Inc, Chicago, IL, USA) was used
for statistical analysis. Statistical signiﬁcance was
determined at P  .05.
RESULTS
Expression of TGIF1 splicing variants by RT-qPCR
Initially, expression of TGIF1 gene (using the generic
primer that may potentially amplify any splicing
variant) was assessed in OSCC samples and their
respective nontumoral margins, and no statistical
difference (P ¼ .20) was found. However, when theTGIF1 splicing variants were individually assessed,
using speciﬁc pairs of primers, the splicing variants
TGIF1v2 and v8 were found to be overexpressed in
OSCC when compared with NT (P ¼ .001 and P ¼ .03,
respectively). Conversely, TGIF1v5 was underex-
pressed in OSCC when compared with NT (P ¼ .034)
(Figure 2). TGIF1v1 and v7 expressions were not
statistically different between OSCC and NT (P ¼ .40
and P ¼ .99, respectively).
There was a strongly positive correlation between the
transcript expression of TGIF1v2 and v8 (R ¼ 0.72,
P ¼ .0002) in the OSCC (Figure 3). A moderately
positive correlation was found between TGIF1 (all
transcripts) and TGIF1v8 (R ¼ 0.61, P ¼ .0020) in the
OSCC. Furthermore, a low positive correlation was
found between TGIF1 (all transcripts) and TGIF1v5
(R ¼ 0.26, P ¼ .10). TGIF1v2 and v5 had a low
negative transcript expression correlation (R ¼ 0.30,
P ¼ .072) (Table III).Correlation between the expression of TGIF1,
TGIF1v8, the clinical-pathologic features, and
disease outcome in OSCC
To establish the relevance of TGIF1 and its splicing
variants’ expression in OSCC, the correlation with
clinical-pathologic features and disease outcome was
assessed. There was an association between low
expression of TGIF1 (all transcripts) and both positive
nodal metastasis (pNþ, P ¼ .013) and advanced path-
ologic TNM stage (III/IV, P ¼ .002) (Figure 4).
Evidence of low expression of TGIF1 in positive
vascular invasion was also observed (P ¼ .094).
Moreover, there was a correlation between a low
expression of TGIF1v8 and both moderate differentia-
tion (P ¼ .005) and positive vascular invasion
(P ¼ .028) (Figure 5). There was also a borderline
correlation between a low expression of TGIF1v8 and
both advanced pathologic TNM stage (III/IV, P ¼ .059)
and positive lymphatic invasion (P ¼ .053).
The univariate analysis revealed that TGIF1 (all
transcripts), TGIF1v2, TGIF1v5, and TGIF1v8 were
not associated with overall survival rates (log-rank test;
P ¼ .20, P ¼ .40, P ¼ .54 and P ¼ .16, respectively).
As expected, a lower overall survival rate was observed
in cases with advanced pathologic TNM stage (III/IV)
compared with cases with an early pathologic TNM
stage (I/II) (P ¼ .004). A lower overall survival rate was
also observed in positive vascular invasion compared
with negative vascular invasion (P < .0001) (data not
shown).
Multivariate analysis also revealed that TGIF1v8
seems to be related to the overall survival over time,
considering tumor size, pathologic TNM stage, histo-
logic grading, perineural invasion, vascular invasion,
Fig. 2. Expression of TGIF1 splicing variants in OSCC and NT groups using RT-qPCR. TGIF1v2 and v8 are overexpressed in
OSCC compared with the nontumoral margin (NT) (P ¼ .001 and P ¼ .03, respectively), whereas TGIF1v5 is underexpressed in
OSCC compared with NT (P ¼ .034, Mann-Whitney Test).
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with an increased risk of cancer-related death (Cox,
P ¼ .066). In this case, an increase of each unit of
TGIF1v8 decreases the chance of cancer-related death
by 41.1% (1-0.59) (Table IV).
Expression of TGIF1 protein by immunohistoche-
mistry. After selection of the representative area of the
tumor and NT samples, the immunohistochemical
feature of TGIF1 was assessed on a TMA with the 24
OSCC and 9 NT. Most cases of OSCC were well
differentiated and had sheets, nests, and highly kerati-
nized tumoral cells. TGIF1 protein was found in all
samples of both groups (OSCC and NT), in both the
cytoplasmic and the nuclear compartments. However,
there was a statistically signiﬁcant score between
groups (discussed later).
The ACIS immunohistochemical scores in the nuclei
compartment ranged from 95.86% to 99.93% of
the tumoral cells. The mean score in the nucleicompartment of NT epithelium was 88.24% (Figure 6,
A). There was a higher nuclear score in tumoral cells
when compared with NT epithelium (P ¼ .004). Also,
the cytoplasmic scores for TGIF1 protein had a higher
positive expression in tumoral cells when compared
with NT epithelium (P ¼ .001).
In the OSCC samples, a moderate positive correla-
tion was found between nuclear and cytoplasmic
staining (P ¼ .0021) (see Table III; see Figure 6, B).
There was no association between nuclear or cytoplasm
proteins expression and the overall patient survival rate
(log-rank test; P ¼ .79 and P ¼ .85, respectively).
DISCUSSION
Based on our ﬁndings, TGIF1v8 may act as an onco-
genic splicing variant during oral carcinogenesis.
However, during the development and invasion of
OSCC, it might change its behavior by decreasing its
expression as the tumor progresses. Our study found
Fig. 3. Correlation of TGIF1 splicing variants expression using RT-qPCR. Dispersion graphic showing the correlation of TGIF1v2
with TGIF1v8 (R ¼ 0.72, P ¼ .0002) and TGIF1 (all transcripts) with TGIF1v8 (R ¼ 0.61, P ¼ .0020) in OSCC.
Table III. Spearman correlation (P value and correlation coefﬁcient r) among age, follow up, nuclear staining, and
variants themselves
OSCC
Follow-up
duration (mo) TGIF1 TGIF1 V2 TGIF1 V5 TGIF1 V8
Nuclear
staining (%)
Cytoplasmic
staining
Age (y)
r 0.21 0.073 0.24 0.092 0.19 0.091 0.30
P 0.16 0.62 0.12 0.57 0.38 0.67 0.15
Follow-up Duration (mo)
r 0.13 0.18 0.29 0.24 0.14 0.30
P 0.40 0.26 0.069y 0.26 0.52 0.15
TGIF1
r 0.25 0.26 0.61 0.27 0.21
P 0.11 0.10y 0.0020* 0.19 0.32
TGIF1v2
r 0.30 0.7199 0.062 0.040
P 0.072y 0.0002* 0.78 0.86
TGIF1v5
r 0.016 0.21 0.22
P 0.95 0.35 0.33
TGIF1v8
r 0.16 0.41
P 0.61 0.17
Nuclear staining (%)
r 0.60
P 0.0021*
*Strong positive correlation for TGIF1v2 with TGIF1v8; moderate positive correlation for TGIF1 with TGIF1v8 and also for nuclear and cyto-
plasmic staining in the OSCC group.
yWeak evidence of low correlation for follow-up duration with TGIF1v5, for TGIF1 with TGIF1v5, and also for TGIF1v2 with TGIF1v5.
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were also differentially expressed in OSCC compared
with NT tissues. However, this study focused on
TGIF1v8, because it was the only splicing variant
among the aforementioned 3 that had a correlation
with the clinical-pathologic characteristics of OSCC
using both a univariate and a multivariate analysis, and
it was particularly associated with advanced stages.
These analyses showed that a low TGIF1v8 expressionwas signiﬁcantly associated with a lower cellular
differentiation (in our samples, moderate differentia-
tion) and positive vascular invasion. We also found
a weak association of low TGIF1v8 expression with
advanced pathologic TNM stage and positive lymphatic
invasion. The multivariate analysis showed that lower
TGIF1v8 values were associated with an increased
risk of cancer related-death, which reinforces the
argument that TGIF1v8 is associated with advanced
Fig. 5. Correlation between TGIF1v8 expression with clinical-pathologic features of OSCC. Low expression of TGIF1v8 in the
group with moderate differentiation (P ¼ .005) and also in the group with positive vascular invasion (P ¼ .028).
Fig. 4. Correlation between TGIF expression and clinical-pathologic features in OSCC. Low expression of TGIF1 (all transcripts)
in the group with positive pathologic lymph node involvement (pNþ, P ¼ .013) and also in the group of advanced pathologic TNM
stage (III/IV) (P ¼ .002).
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of TGIF1v8 reduces the chance of cancer-related death
by 41.1%.TGIF1v2, v5, and v8 are differentially expressed in
OSCC when compared with NT
TGIF1, a transcription factor of the homeobox family,
has been implicated in a number of distinct pathways.
This study shows for the ﬁrst time that TGIF1v2, v5,
and v8 were differentially expressed in OSCC when
compared with NT. TGIF1v2 and v8 may act as
oncogenic variants, because they were overexpressed inOSCC, whereas TGIF1v5 possibly acts as a tumor
suppressor, because it was underexpressed in OSCC in
relation to NT samples. Also, TGIF1v2 and v8 might
play similar roles in oral carcinogenesis, because
a strong positive correlation between them was found.
However, TGIF1v8 might represent, within our
samples, the putative splicing variant that has the most
relevant expression in tumoral cells, owing to its
moderate correlation to TGIF1.
A previous in situ hybridization study showed that
TGIF1 transcripts had a signal that was frequently
intense in NT, and generally weak in OSCC,14 sug-
gesting that TGIF1 expression is higher in NT
Fig. 6. The TGIF1 protein was found in all OSCC and NT samples, in both the cytoplasmic and the nuclear compartments,
although a statistically signiﬁcant score difference between groups was found. A, TGIF1 expression in NT epithelium in both the
cytoplasmic and the nuclear compartments (100). B, TGIF1 expression in OSCC in both the cytoplasmic and the nuclear
compartments (100; inset, 400).
Table IV. Results of the Cox model set in the presence of TGIF1v8
Effect Standard error P value Odds ratio CI 95%, OR
Initial model
pT 2.85 1.80 0.11 17.32 0.51, 589.05
pTNM 2.24 1.73 0.20 0.11 0, 3.15
Histologic grading 0.049 1.27 0.97 1.050 0.090, 12.71
Perineural invasion 0.29 0.93 0.76 0.75 0.12, 4.60
Vascular invasion 1.37 1.32 0.30 3.95 0.30, 52.48
Lymphatic invasion 2.0 1.50 0.18 0.14 0.010, 2.56
TGIF1_v8 0.70 0.50 0.16 0.50 0.19, 1.31
Final model
TGIF1_v8_tumor 0.53 0.29 0.066 0.59 0.34, 1.040
pT, tumor size; pTNM, pathologic TNM stage; CI, conﬁdence interval; OR, odds ratio.
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we found no differences regarding TGIF1 expression in
OSCC when compared with NT, although an imbalance
of speciﬁc splicing variants (TGIF1v2, TGIF1v5, and
TGIF1v8) was found, which suggests that alternative
splicing of TGIF1 may be deregulated in OSCC. The
lack of difference between OSCC and NT samples,
when amplifying all TGIF1 transcripts, is probably
because of the interference of imbalanced splicing
variants.
The analysis of the TGIF1 protein showed that there
was a statistically signiﬁcant difference between the
nuclear and cytoplasmic expression when comparing
OSCC and NT samples. In line with Matizonkas et al.
(2011),14 we agree that TGIF1 cytoplasmic immuno-
localization implies that some isoforms could develop
additional functions other than transcription. Further-
more, Lo et al. (2001)29 revealed that the mitogen-
activated protein kinase transducing pathway can
phosphorylate TGIF1, prolonging its half-life and
consequently raising its protein level, which could also
justify the higher levels of TGIF1 protein in the cyto-
plasmic compartment of OSCC cells. It has previously
been found that EGF-Ras-Mek pathway deregulation is
associated with OSCC proliferation.30 Unfortunately,speciﬁc antibodies against TGIF1 protein isoforms are
not commercially available. Additional studies to
examine speciﬁc TGIF1 isoforms are necessary to
clarify the exact role of each isoform and also the role
of such isoforms in oral carcinogenesis.Correlation between expression of TGIF1,
TGIF1v2, and v8 and the clinical-pathologic
features and disease outcome in OSCC
TGIF1 is a homeobox transcriptional repressor that is
implicated in several biologic and pathologic processes.
Its role in carcinogenesis is still unclear, because there
are hardly any studies in the literature regarding TGIF1
expression in cancers. It has been reported that TGIF1
is expressed in cancers of the esophagus, stomach,
and liver17-20; in leukemia17-20; and (as more recently
reported) in oral cancer.14 Some of these studies have
suggested that TGIF1 is implicated in tumor develop-
ment or progression, but none of them found an asso-
ciation between TGIF1 and prognostic factors. This
study presents data that are consistent with a possible
role of TGIF1 in oral carcinogenesis, especially
TGIF1v8, because this splicing variant was correlated
with prognostic factors. Hamid et al.10,20 found
OOOO ORIGINAL ARTICLE
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myeloid leukemia, suggesting that TGIF1 may regulate
the balance between proliferation and differentiation.
There are several reports in the literature of alternative
splicing variants being potential biomarkers.22,31
Although TGIF1v2 and TGIF1v8 overexpression may
play an important role in oral carcinogenesis, it is crucial
to decipher the mechanisms underlying aberrant splicing
in cancer to understand how splicing machinery is
controlled and integrated with other cellular processes,
in particular transcription and signaling pathways.32
Furthermore, patterns of alternative splicing can be
tissue-speciﬁc, stimulus-speciﬁc, disease-speciﬁc, or
a combination of these, and the presence or level of
speciﬁc splice variants, even without knowledge of their
activity, may provide useful biomarkers that can be
causative of disease, can be involved in disease devel-
opment, or can act as surrogate markers. Either way,
targeted clinical studies are required to conﬁrm their
usefulness in the diagnosis and monitoring of cancer.22
However, caution is advised, because previous clinical
trials for advanced head and neck carcinoma, using
bivatuzumab mertansine (a cytotoxic immunoconjugate)
speciﬁcally targeting CD44v6,33 had to be discontinued
because of the occurrence of skin toxicity.34
It has previously been found, by in situ hybridization,
that there is a weaker transcript signal of TGIF1 tran-
scripts in poorly differentiated areas of OSCC when
compared with both well-differentiated and adjacent
NT.14 These ﬁndings are not in accordance with the
absence of difference between OSCC and NT when all
transcripts were analyzed using the generic primer for
TGIF1. This fact may be explained by the different
techniques used. In situ hybridization enables an indi-
vidualized cell to be analyzed, whereas RT-qPCR
ampliﬁes mRNA of all cells present in a tumoral area.
However, in this study, which used RT-qPCR to target
speciﬁc splice variants, a low expression of TGIF1v8
was correlated with moderately differentiated OSCC
when compared with well-differentiated OSCC. The
correlation of TGIF1 with its splicing variant TGIF1v8
has been previously discussed.
On the other hand, low expression of TGIF1 (all
transcripts) was related to advanced pathologic TNM
stage (III/IV) and node-positive carcinomas of the oral
cavity and was probably also related to a low expres-
sion of TGIF1v2 and v8, because they may act in
a similar way, judging by their correlation. However,
the multivariate analysis did not show the association
between isolated splice variants with clinical-pathologic
features and the overall survival, except for TGIF1v8,
where lower values seem to be associated with an
increased risk of cancer-related death. Hamid et al.
(2008)10 showed that the expression of TGIF1 splicing
variants is similar in leukemia, except for isoform 4,which had a very low expression level. The same group
(Hamid et al., 2009)20 reported that reduced TGIF1
(generic form) expression could lead to quiescence,
thus providing progenitor as well as hematopoietic stem
cells protection from anticycle agents, and they sug-
gested that TGIF1 has an important role in myelopoi-
esis and may regulate the balance between proliferation
and differentiation. In general, many studies show that
splicing variants are cell speciﬁc. Well-known CD44
splicing variants as examples of cancer biomarkers have
been reviewed.22 In brief, antibodies directed against
CD44v6 have been shown to efﬁciently target head and
neck squamous cell carcinoma and have been proposed
for tumor imaging.22 CD44v10 expression can appar-
ently differentiate between metastatic and nonmetastatic
pancreatic cancer cells; CD44v6 can serve as an
indicator of tumor progression in gastric carcinoma;
CD44v7 to v9 are overexpressed in prostate cancer
tissues; CD44v5 expression correlates with the aggres-
siveness of thymic epithelial tumors; and decreased
levels of CD44v3 and CD44v6 possibly correlate with
sputum cytologyenegative cases of lung cancer.22
Although TGIF1v8 was found overexpressed in
OSCC when compared with NT, this ﬁnding is not
necessarily relevant regarding tumor aggressiveness.
Our ﬁndings show that as OSCC progresses, the
expression of TGIF1v8 decreases. One possible expla-
nation is that this gene has a dual role during carcino-
genesis, similar to what has been reported for TGFb
(transforming growth factor beta).35
TGIF1 and TGFb may have both antagonists and
similar roles in carcinogenesis. It is known that TGIF1
acts as a transcriptional corepressor of the signaling
pathway activated by TGFb, and it can also be regu-
lated by TGFb, which indicates a negative feedback
mechanism.16,36 The TGFb pathway is complex,
especially because it can play a dual role in cancer,
acting as a tumor suppressor in early stages and as an
oncogene in later stages of carcinogenesis.35-37 Based
on our results, we suggest that TGIF1v8 acts as an
oncogene in early stages and as a tumor suppressor in
advanced stages of carcinogenesis, unlike TGFb. This
is probably due to a negative feedback mechanism that
TGFb may exert on TGIF1v8.
Matizonkas et al. (2011)14 reported that the simul-
taneous localization of TGIF1 in both the cytoplasm
and the nucleus was correlated with poorly differenti-
ated cases. In our study, there was no distinct difference
between the nuclear and cytoplasmic protein staining in
relation with clinical-pathologic data, which suggests
that the TGIF1 protein is not a marker of OSCC
prognosis. The availability of speciﬁc antibodies to
study the expression of individual TGIF1 isoforms may
challenge this concept, as suggested by our TGIF1v2
versus v8 data.
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There was no difference between the transcripts of
TGIF1 found in OSCC and NT samples, although there
is an imbalance of speciﬁc splicing variants, which
suggests that alternative splicing of TGIF1 is deregu-
lated in OSCC. The data presented support a signiﬁcant
association between low expression of TGIF1v8 with
lower cellular differentiation and positive vascular
invasion. A weak association was also found between
low TGIF1v8 expression and advanced pathologic
TNM stage and positive lymphatic invasion. Finally,
low TGIF1 expression is associated with positive nodal
metastasis and advanced pathologic TNM staging.
Taking these considerations together, our data suggest
that TGIF1v8 is overexpressed in OSCC and is related
to pathologic and clinical behavior.
The authors are thankful to Dr Edward K. Chan for critical
reading of this manuscript.
REFERENCES
1. Walker DM, Boey G, Mcdonald LA. The pathology of oral
cancer. Pathology. 2003;35:376-383.
2. Brinkman BM, Wong DT. Disease mechanism and biomarkers of
oral squamous cell carcinoma. Curr Opin Oncol. 2006;18:228-
233.
3. Kim MM, Califano JA. Molecular pathology of head-and-neck
cancer. Int J Cancer. 2004;112:545-553.
4. Sotiriou C, Lothaire P, Dequanter D, Cardoso F, Awada A.
Molecular proﬁling of head and neck tumors. Curr Opin Oncol.
2004;16:211-214.
5. Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J
Clin. 2005;55:10-30.
6. Massano J, Regateiro FS, Januario G, Ferreira A. Oral squa-
mous cell carcinoma: review of prognostic and predictive
factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.
2006;102:67-76.
7. Zheng M, Li L, Tang YL, Liang XH. Biomarkers in tongue
cancer: understanding the molecular basis and their clinical
implications. Postgrad Med J. 2010;86:292-298.
8. Grier DG, Thompson A, Kwasniewska A, Mcgonigle GJ,
Halliday HL, Lappin TR. The pathophysiology of HOX genes
and their role in cancer. J Pathol. 2005;205:154-171.
9. Krumlauf R. Hox genes in vertebrate development. Cell. 1994;78:
191-201.
10. Hamid R, Patterson J, Brandt SJ. Genomic structure, alternative
splicing and expression of TG-interacting factor, in human
myeloid leukemia blasts and cell lines. Biochim Biophys Acta.
2008;1779:347-355.
11. Zhu F, Li J, Li WX, Liu ZC, Long X. Overexpression and
clinicopathological signiﬁcance of homeobox gene Quox-1 in
oral squamous cell carcinoma. J Biochem Mol Biol. 2004;37:
671-675.
12. Hassan NM, Hamada J, Murai T, et al. Aberrant expression of
HOX genes in oral dysplasia and squamous cell carcinoma
tissues. Oncol Res. 2006;16:217-224.
13. De Souza Setubal Destro MF, Bitu CC, Zecchin KG, et al.
Overexpression of HOXB7 homeobox gene in oral cancer
induces cellular proliferation and is associated with poor prog-
nosis. Int J Oncol. 2010;36:141-149.14. Matizonkas-Antonio LF, Liborio TN, Aquino Xavier FC, Silva-
Valenzuela MD, Michaluarte-Júnior P, Nunes FD. Detection of
TGIF1 homeobox gene in oral squamous cell carcinoma
according to histologic grading. Oral Surg Oral Med Oral Pathol
Oral Radiol Endod. 2011;111:218-224.
15. Liborio TN, Acquafreda T, Matizonkas-Antonio LF, Silva-
Valenzuela MD, Michaluarte-Júnior P, Nunes FD. In situ
hybridization detection of homeobox genes reveals distinct
expression patterns in oral squamous cell carcinomas. Histopa-
thology. 2011;58:225-233.
16. Wotton D, Knoepﬂer PS, Laherty CD, Eisenman RN,
Massagué J. The Smad transcriptional corepressor TGIF recruits
mSin3. Cell Growth Differ. 2001;12:457-463.
17. Nakakuki K, Imoto I, Pimkhaokham A, et al. Novel targets for the
18p11.3 ampliﬁcation frequently observed in esophageal squa-
mous cell carcinomas. Carcinogenesis. 2002;23:19-24.
18. Hu ZL, Wen JF, Xiao DS, Zhen H, Fu CY. Effects of
transforming growth interacting factor on biological behav-
iors of gastric carcinoma cells. World J Gastroenterol.
2005;11:84-88.
19. Borlak J, Meier T, Halter R, Spanel R, Spanel-Borowski K.
Epidermal growth factor-induced hepatocellular carcinoma: gene
expression proﬁles in precursor lesions, early stage and solitary
tumours. Oncogene. 2005;24:1809-1819.
20. Hamid R, Brandt SJ. Transforming growth-interacting factor
(TGIF) regulates proliferation and differentiation of human
myeloid leukemia cells. Mol Oncol. 2009;3:451-463.
21. Venables JP. Aberrant and alternative splicing in cancer. Cancer
Res. 2004;64:7647-7654.
22. Brinkman BM. Splice variants as cancer biomarkers. Clin Bio-
chem. 2004;37:584-594.
23. Bartel F, Taubert H, Harris LC. Alternative and aberrant
splicing of MDM2 mRNA in human cancer. Cancer Cell.
2002;2:9-15.
24. Jiang Z, Cote J, Kwon JM, Goate AM, Wu JY. Aberrant splicing of
tau pre-mRNA caused by intronic mutations associated with the
inherited dementia frontotemporal dementia with parkinsonism
linked to chromosome 17. Mol Cell Biol. 2000;20:4036-4048.
25. Hyman BT, Augustinack JC, Ingelsson M. Transcriptional and
conformational changes of the tau molecule in Alzheimer’s
disease. Biochim Biophys Acta. 2005;1739:150-157.
26. Ferreira EN, Rangel MC, Galante PF, et al. Alternative splicing
enriched cDNA libraries identify breast cancer-associated tran-
scripts. BMC Genomics. 2010;11(suppl 5):S4.
27. Johnson N, Frenceschi S, Ferlay J, et al. Squamous cell carci-
noma. In: Barnes L, Eveson JW, Reichart P, Sidransky D, eds.
World Health Organization Classiﬁcation of Tumours. Pathology
and Genetics of Head and Neck Tumours. Lyon, France: IARC
Press; 2005:168-175.
28. Pfafﬂ MW. A new mathematical model for relative quantiﬁcation
in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.
29. Lo RS, Wotton D, Massague J. Epidermal growth factor signaling
via Ras controls the Smad transcriptional co-repressor TGIF.
EMBO J. 2001;20:128-136.
30. Mishima K, Inoue K, Hayashi Y. Overexpression of extracellular-
signal regulated kinases on oral squamous cell carcinoma. Oral
Oncol. 2002;38:468-474.
31. Omenn GS, Yocum AK, Menon R. Alternative splice variants,
a new class of protein cancer biomarker candidates: ﬁndings in
pancreatic cancer and breast cancer with systems biology impli-
cations. Dis Markers. 2010;28:241-251.
32. Ghigna C, Valacca C, Biamonti G. Alternative splicing and tumor
progression. Curr Genomics. 2008;9:556-570.
33. Colnot DR, Roos JC, de Bree R, et al. Safety, biodistribution,
pharmacokinetics, and immunogenicity of 99mTc-labeled
OOOO ORIGINAL ARTICLE
Volume 116, Number 5 Libório et al. 625humanized monoclonal antibody BIWA 4 (bivatuzumab) in
patients with squamous cell carcinoma of the head and neck.
Cancer Immunol Immunother. 2003;52:576-582.
34. PajaresMJ, Ezponda T, Catena R, CalvoA, Pio R,Montuenga LM.
Alternative splicing: an emerging topic in molecular and clinical
oncology. Lancet Oncol. 2007;8:349-357.
35. Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role
of transforming growth factor beta in mammary tumorigenesis and
metastatic progression. Clin Cancer Res. 2005;11:937-943.
36. Chen F, Ogawa K, Nagarajan RP, Zhang M, Kuang C, Chen Y.
Regulation of TG-interacting factor by transforming growth factor
b. Biochem J. 2003;371:257-263.37. Elliott RL, Blobe GC. Role of transforming growth factor beta in
human cancer. J Clin Oncol. 2005;23:2078-2093.
Reprint requests:
Tatiana Nayara Libório, DDS, PhD
Pathology and Legal Medicine Department
Federal University of Amazonas
Av. Valdemar Pedrosa, 1097
Manaus, Amazonas, 69020-160
Brazil
tliborio@ufam.edu.br; tatiana.liborio@gmail.com
